2016 Q3 Form 10-Q Financial Statement

#000114420416119035 Filed on August 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q3
Revenue $4.257M
YoY Change 45.4%
Cost Of Revenue $1.162M
YoY Change 38.87%
Gross Profit $3.095M
YoY Change 48.02%
Gross Profit Margin 72.71%
Selling, General & Admin $760.0K
YoY Change 52.0%
% of Gross Profit 24.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $282.3K
YoY Change 22.42%
% of Gross Profit 9.12%
Operating Expenses $1.590M
YoY Change 35.9%
Operating Profit $1.171M
YoY Change 95.0%
Interest Expense $339.7K
YoY Change 7.46%
% of Operating Profit 29.02%
Other Income/Expense, Net -$857.00
YoY Change -74.73%
Pretax Income $1.170M
YoY Change 95.96%
Income Tax $866.00
% Of Pretax Income 0.07%
Net Earnings $813.1K
YoY Change 104.92%
Net Earnings / Revenue 19.1%
Basic Earnings Per Share
Diluted Earnings Per Share $48.50K
COMMON SHARES
Basic Shares Outstanding 13.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $600.0K
YoY Change 27.66%
Cash & Equivalents $597.0K
Short-Term Investments
Other Short-Term Assets $540.0K
YoY Change 315.38%
Inventory $810.0K
Prepaid Expenses
Receivables $2.400M
Other Receivables $1.580M
Total Short-Term Assets $5.930M
YoY Change 117.22%
LONG-TERM ASSETS
Property, Plant & Equipment $24.38M
YoY Change 7.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.070M
YoY Change 5.94%
Total Long-Term Assets $25.44M
YoY Change 7.03%
TOTAL ASSETS
Total Short-Term Assets $5.930M
Total Long-Term Assets $25.44M
Total Assets $31.37M
YoY Change 18.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $910.0K
YoY Change 160.0%
Accrued Expenses $50.00K
YoY Change 25.0%
Deferred Revenue
YoY Change
Short-Term Debt $434.8K
YoY Change -14.75%
Long-Term Debt Due $2.170M
YoY Change 28.4%
Total Short-Term Liabilities $3.639M
YoY Change 38.9%
LONG-TERM LIABILITIES
Long-Term Debt $16.91M
YoY Change -2.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $16.91M
YoY Change -2.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.639M
Total Long-Term Liabilities $16.91M
Total Liabilities $20.55M
YoY Change -12.16%
SHAREHOLDERS EQUITY
Retained Earnings $5.350M
YoY Change
Common Stock $1.146M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.041M
YoY Change
Total Liabilities & Shareholders Equity $31.37M
YoY Change 18.39%

Cashflow Statement

Concept 2016 Q3
OPERATING ACTIVITIES
Net Income $813.1K
YoY Change 104.92%
Depreciation, Depletion And Amortization $282.3K
YoY Change 22.42%
Cash From Operating Activities $490.0K
YoY Change -43.68%
INVESTING ACTIVITIES
Capital Expenditures -$480.0K
YoY Change -64.18%
Acquisitions
YoY Change
Other Investing Activities $430.0K
YoY Change -23.21%
Cash From Investing Activities -$50.00K
YoY Change -93.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -710.0K
YoY Change 173.08%
NET CHANGE
Cash From Operating Activities 490.0K
Cash From Investing Activities -50.00K
Cash From Financing Activities -710.0K
Net Change In Cash -270.0K
YoY Change 58.82%
FREE CASH FLOW
Cash From Operating Activities $490.0K
Capital Expenditures -$480.0K
Free Cash Flow $970.0K
YoY Change -56.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
12593 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4757 USD
CY2016Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3488 USD
CY2015Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
53 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24898867 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23745925 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1757150 USD
CY2012Q4 jrss Joint Venture Investment Obligation To Pay Capital
JointVentureInvestmentObligationToPayCapital
35000000 CNY
CY2013Q2 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.7 pure
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1735055 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
686074 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
2099133 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
1151846 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
14081819 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
18907433 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
1574635 USD
jrss Capital Lease Financing Fees
CapitalLeaseFinancingFees
697383 USD
jrss Capital Lease Financing Fees
CapitalLeaseFinancingFees
568821 USD
jrss Consulting Fee
ConsultingFee
34513 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1298014 USD
CY2016Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2343601 USD
CY2015Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
2035271 USD
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25210 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25802 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.25 pure
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001597892
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
JRSS
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13915000 shares
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
JRSIS HEALTH CARE Corp
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13915000 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13915000 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13915000 shares
us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
488615 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
0 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
140376 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 30pt; FONT: 10pt Times New Roman, Times, Serif"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div><i>C.</i></div> </td> <td> <div><i>Use of estimates</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities&#160;at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable.&#160;Actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"> <div><i>E.</i></div> </td> <td> <div><i>Concentration of Credit Risk</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the six months ended June 30, 2016 and 2015, no customer accounted for more than 10% of net revenue. As of June 30, 2016 and December 31, 2015, 2 and 1 customer accounted for more than 10% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
609950 USD
CY2015Q4 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
76495 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2012Q4 jrss Joint Venture Investment Obligation To Pay Capital
JointVentureInvestmentObligationToPayCapital
5555556 USD
us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
0 USD
CY2015 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
0 USD
jrss Consulting Fee
ConsultingFee
3971 USD
CY2016Q2 jrss Consulting Fee
ConsultingFee
17267 USD
CY2015Q2 jrss Consulting Fee
ConsultingFee
3971 USD
CY2016Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
6910 USD
CY2015Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
9477 USD
CY2016Q2 jrss Capital Lease Financing Fees
CapitalLeaseFinancingFees
353904 USD
CY2015Q2 jrss Capital Lease Financing Fees
CapitalLeaseFinancingFees
292866 USD
us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
680245 USD
CY2013Q2 jrss Capital Leases Frequency Of Periodic Payment
CapitalLeasesFrequencyOfPeriodicPayment
annual

Files In Submission

Name View Source Status
0001144204-16-119035-index-headers.html Edgar Link pending
0001144204-16-119035-index.html Edgar Link pending
0001144204-16-119035.txt Edgar Link pending
0001144204-16-119035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
jrss-20160630.xml Edgar Link completed
jrss-20160630.xsd Edgar Link pending
jrss-20160630_cal.xml Edgar Link unprocessable
jrss-20160630_def.xml Edgar Link unprocessable
jrss-20160630_lab.xml Edgar Link unprocessable
jrss-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v446449_10q.htm Edgar Link pending
v446449_ex31-1.htm Edgar Link pending
v446449_ex31-2.htm Edgar Link pending
v446449_ex32-1.htm Edgar Link pending
v446449_ex32-2.htm Edgar Link pending